Genfit S.A. Total Liabilities
Genfit S.A. total liabilities. Based on the latest financial reports, Genfit S.A. (GNFT) has total liabilities worth $164.21 Million USD as of June 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check Genfit S.A. (GNFT) liquid assets ratio to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Genfit S.A. (2004–2024)
Total liabilities of Genfit S.A. from 2004 to 2024. This chart illustrates how Genfit S.A.'s total liabilities have evolved over time, based on quarterly financial data. Explore Genfit S.A. (GNFT) investment intensity to see how much of total assets are deployed in long-term investments.
Genfit S.A. Competitors by Total Liabilities
The table below lists competitors of Genfit S.A. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Bang & Olufsen
CO:BO
|
Denmark | Dkr1.22 Billion |
|
SHANDONG BOAN BIOTECH.H 1
F:UJ9
|
Germany | €1.39 Billion |
|
GDI Property Group
AU:GDI
|
Australia | AU$425.93 Million |
|
Apollo Pipes Limited
NSE:APOLLOPIPE
|
India | Rs2.91 Billion |
|
Sino AG
F:XTP
|
Germany | €2.38 Million |
|
Shattuck Labs Inc
NASDAQ:STTK
|
USA | $7.09 Million |
|
Pioneer High Income Closed Fund
NYSE:PHT
|
USA | $116.53 Million |
Liability Composition Analysis (2004–2024)
This chart breaks down Genfit S.A.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see GNFT total assets.
Liquidity & Leverage Metrics
Genfit S.A. Total Liabilities Ratios Explained
Genfit S.A. total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 3.74 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 3.13 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.76 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Genfit S.A.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Genfit S.A. (2004–2024)
The table below shows the annual total liabilities of Genfit S.A. from 2004 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $82.20 Million | -22.39% |
| 2023-12-31 | $105.92 Million | -12.47% |
| 2022-12-31 | $121.01 Million | -25.59% |
| 2021-12-31 | $162.62 Million | -24.28% |
| 2020-12-31 | $214.78 Million | -4.88% |
| 2019-12-31 | $225.79 Million | +8.27% |
| 2018-12-31 | $208.54 Million | +10.36% |
| 2017-12-31 | $188.95 Million | +706.91% |
| 2016-12-31 | $23.42 Million | +69.17% |
| 2015-12-31 | $13.84 Million | -13.15% |
| 2014-12-31 | $15.94 Million | +5.84% |
| 2013-12-31 | $15.06 Million | -10.09% |
| 2012-12-31 | $16.75 Million | -31.97% |
| 2011-12-31 | $24.62 Million | +7.05% |
| 2010-12-31 | $23.00 Million | +0.39% |
| 2009-12-31 | $22.91 Million | -2.98% |
| 2008-12-31 | $23.61 Million | +59.04% |
| 2007-12-31 | $14.85 Million | -19.64% |
| 2006-12-31 | $18.47 Million | +5.88% |
| 2005-12-31 | $17.45 Million | +5.06% |
| 2004-12-31 | $16.61 Million | -- |
About Genfit S.A.
Genfit S.A., a late-stage biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company develops Elafibranor, which is in Phase III clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fi… Read more